The Zhitong Finance App learned that as competition between the two pharmaceutical giants continues to escalate, Novo Nordisk (NVO.US) has filed a lawsuit in the US federal court, accusing LLY.US (LLY.US) of misleading advertisements for its best-selling diet drug Zepbound and the diabetes injectable drug Mounjaro.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.